🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis

RecruitingPhase 1, Phase 2Ages 18 Years - 75 YearsAllLeal Therapeutics, Inc
NCT07660614 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study will examine what happens when patients with amyotrophic lateral sclerosis (ALS) are given an investigational medication (study drug) known as LTX-002. Specifically, the researchers will be looking at safety, tolerability (if someone has any side effects from the drug), pharmacokinetics (what the body does to the study drug) and pharmacodynamics (what the study drug does to the body). The study will also investigate the effect of the drug on indicators of the severity of ALS, such as markers in blood and in the cerebrospinal fluid (the fluid that surrounds the brain and spinal cord, CSF) and on measures of the participant's ability to move, speak, and breathe.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of ALS per Gold Coast criteria * ALS symptom onset less than 36 months prior to Screening * Slow vital capacity ≥ 50% of predicted value * Body mass index ≥18 and ≤40 kg/m2 Exclusion Criteria: * Current evidence or history of a clinically significant medical condition that, in the Investigator's judgement, would impact the participant's safety, interpretation of study results, or place the participant at high risk of poor treatment compliance or of not completing the study * History of brain or spinal abnormalities on magnetic imaging (MRI) or computed tomography (CT) that might interfere with the lumbar puncture (LP), cerebrospinal fluid (CSF) circulation or safety assessments * Prior treatment with antisense oligonucleotide (ASO), small interfering RNA, stem cell therapy, or gene therapy for any indication * Tracheostomy * HIV, Hepatitis B or C infection (acute or chronic) * Presence of implanted shunt (CSF) or vascular device * Risk for uncontrolled bleeding * Pregnant or breastfeeding
💊

What it tests

  • LTX-002
  • Placebo (aCSF)
📍

Where

5 sites
University Hospital Schleswig-Holstein, Campus Lübeck
Lübeck, Germany
Istituto Neurologico "Carlo Besta"
Milan, Italy
AOU Città della Salute e della Scienza di Torino
Torino, Italy
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
Karolinska Universitetssjukhuset
Stockholm, Sweden
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy